IP Library Granted Patent US 11,173,158
Granted Patent B2
US 11,173,158 · App. 16/444,396 · Granted Nov 16, 2021

Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same

Inventors: Hiroyuki Hasegawa (Tokyo, JP); Shin Aizawa (Tokyo, JP)
Assignees: PTC Therapeutics MP, Inc.; Shiratori Pharmaceuticals Co., Ltd.
A61K31/519A23L2/52A23L33/10C07D475/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,173,158
App. No.
16/444,396
Granted
Nov 16, 2021
Kind
B2
Abstract

Disclosed is a means for improving the symptoms of a cerebral dysfunction. The present inventors made a new discovery that the activity of brain aromatic monoamines increases when sepiapterin is administered peripherally. Disclosed, therefore, is a medicinal agent, which contains at least sepiapterin or a salt thereof, for preventing or improving cerebral dysfunction. Also disclosed is a beverage/food, which contains at least sepiapterin or a salt thereof, for preventing or improving cerebral dysfunction. Unlike tetrahydrobiopterin and the like, sepiapterin can control reductions in the brain neuron levels of brain aromatic monoamines (serotonin, dopamine, noradrenaline, and the like) and increase the activity thereof even when administered peripherally. Therefore, sepiapterin may be effective for cerebral dysfunctions, which are due to reductions in the brain neuron levels of brain aromatic monoamines, such as depression, bulimia, autism, impaired consciousness and concentration, cognitive disorders and other central mental disorders, as well as myotonia, rigidity, tremors, and other central motor disorders.

Claims (8)

1. A method of preventing or improving cerebral dysfunction in a subject with a central motor disorder, the method comprising peripherally administering a composition which contains at least sepiapterin to the subject with cerebral dysfunction, wherein the central motor disorder is myotonia, and wherein the composition is administered in an amount sufficient to suppress a decrease in aromatic monoamines in the brain.

2. The method of claim 1 , wherein the composition is a food or drink which contains sepiapterin as an active ingredient.

3. The method of claim 1 , wherein the composition is administered at a dose of 0.1 to 100 mg/kg of sepiapterin.

4. The method of claim 1 , wherein the aromatic monoamines comprise serotonin, dopamine, adrenaline, and/or noradrenaline.

5. The method of claim 1 , wherein the composition is a food or drink which contains sepiapterin as an active ingredient.

6. The method of claim 1 , wherein the composition is administered at a dose of 0.1 to 100 mg/kg of sepiapterin.

7. The method of claim 1 , wherein the composition further comprises a pharmacologically acceptable carrier.

8. The method of claim 1 , wherein the composition further comprises a pharmacologically acceptable carrier.

Assignments (7)
TERMINATION AND RELEASE OF PATENT SECURITY AGREEMENT @ REEL 061584 AND FRAME 0377 Recorded Oct 23, 2023
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: PTC THERAPEUTICS MP, INC.
Reel/Frame 065321/0025 →
SECURITY INTEREST Recorded Oct 28, 2022
From: PTC THERAPEUTICS MP, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 061584/0377 →
CHANGE OF NAME Recorded Jul 23, 2020
From: CENSA PHARMACEUTICALS INC.
To: PTC THERAPEUTICS MP, INC.
Reel/Frame 053300/0057 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2019
From: NIHON UNIVERSITY
To: HASEGAWA, HIROYUKI
Reel/Frame 049863/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2019
From: CENSA PHARMACEUTICALS INC.
To: SHIRATORI PHARMACEUTICALS CO., LTD.; CENSA PHARMACEUTICALS INC.
Reel/Frame 049872/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2019
From: HASEGAWA, HIROYUKI
To: CENSA PHARMACEUTICALS INC.
Reel/Frame 049863/0573 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2019
From: HASEGAWA, HIROYUKI; AIZAWA, SHIN
To: NIHON UNIVERSITY
Reel/Frame 049872/0175 →
Priority Claims (1)
JP 2010-098602 · Apr 22, 2010 · national
Continuity (3)
Continuation 15823826 · Nov 28, 2017
Continuation 13642639
Related Publication 20200009145A1 · Jan 9, 2020
Cited By (8)
US 12,213,982 US 12,257,252 US 12,269,829 US 12,325,706 US 12,329,757 US 12,637,465 US 12,667,569 US 12,691,119